search
Back to results

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
Japan
Study Type
Interventional
Intervention
TA-7284-Low
TA-7284-Low-middle
TA-7284-High-middle
TA-7284-High
Placebo
Sponsored by
Mitsubishi Tanabe Pharma Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring TA-7284, JNJ-28431754, Canagliflozin, Type 2 diabetes mellitus, Sodium Glucose Co-transporter (SGLT2 inhibitor)

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged from 20 to 80 years inclusive on the day of informed consent;
  • Patients who was diagnosed with type 2 diabetes mellitus at least 3 months before the start of the run-in period;
  • Patients with HbA1c of ≥6.5% and ≤9.5% (according to the Japan Diabetic Society [JDS] criteria) on the start day of the run-in period;

Exclusion Criteria:

  • Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.);
  • Past or current history of severe diabetic complications (proliferative diabetic retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or serious diabetic neuropathy);
  • Fasting blood glucose of >270 mg/dL on the start day of the run-in period or at Week 2 of the run-in period;
  • eGFR of <60 mL/min/1.73 m2 on the start day of the run-in period;
  • Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the start or end day of the run-in period;
  • History of myocardial infarction, unstable angina, or cerebrovascular disorder within 3 months before the start of the run-in period;
  • Concurrent serious (e.g., requiring inpatient hospitalization or surgical intervention) renal or hepatic disease;
  • Past or current history of malignant tumor; however, this criterion shall not apply to those who have been free of relapse for at least 5 years even with a history of malignant tumor.
  • Past or current history of drug hypersensitivity such as shock and anaphylactoid symptoms;
  • Pregnant women, lactating mothers, or women of childbearing potential;
  • Any condition that subjects are assessed to be ineligible by the investigator (sub investigator).

Sites / Locations

  • Research site
  • Research site
  • Research site
  • Research site
  • Research site
  • Research site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

TA-7284-Low

TA-7284-Low-middle

TA-7284-High-middle

TA-7284-High

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value)

Secondary Outcome Measures

Fasting Blood Glucose, Body Weight
Safety and Tolerability

Full Information

First Posted
November 29, 2009
Last Updated
May 27, 2014
Sponsor
Mitsubishi Tanabe Pharma Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT01022112
Brief Title
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally-Administered SGLT2 Inhibitor TA-7284
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
September 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mitsubishi Tanabe Pharma Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.
Detailed Description
Type 2 diabetes mellitus (T2DM) is well recognized as a major public health problem that presents patients with a significant risk of complications including heart disease, retinopathy, nephropathy, and neuropathy. Various classes of orally administered antihyperglycemic agents have been developed for the treatment of T2DM and although individual agents may be highly effective for some patients, it is still difficult to maintain optimal glycemic control in most patients, resulting in high rates of morbidity and mortality in the diabetic population. This is a randomized, double-blind, placebo-controlled, parallel-group study to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with T2DM, who are not optimally controlled on diet and exercise. The primary study hypothesis is that the study drug will be superior to placebo as assessed by the change in HbA1c from baseline. The patients will receive tablets of TA-7284, or placebo, once daily for 12 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
TA-7284, JNJ-28431754, Canagliflozin, Type 2 diabetes mellitus, Sodium Glucose Co-transporter (SGLT2 inhibitor)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
383 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TA-7284-Low
Arm Type
Experimental
Arm Title
TA-7284-Low-middle
Arm Type
Experimental
Arm Title
TA-7284-High-middle
Arm Type
Experimental
Arm Title
TA-7284-High
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
TA-7284-Low
Intervention Description
TA-7284-Low
Intervention Type
Drug
Intervention Name(s)
TA-7284-Low-middle
Intervention Description
TA-7284-Low-middle
Intervention Type
Drug
Intervention Name(s)
TA-7284-High-middle
Intervention Description
TA-7284-High-middle
Intervention Type
Drug
Intervention Name(s)
TA-7284-High
Intervention Description
TA-7284-High
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Fasting Blood Glucose, Body Weight
Time Frame
12 weeks
Title
Safety and Tolerability
Time Frame
14 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged from 20 to 80 years inclusive on the day of informed consent; Patients who was diagnosed with type 2 diabetes mellitus at least 3 months before the start of the run-in period; Patients with HbA1c of ≥6.5% and ≤9.5% (according to the Japan Diabetic Society [JDS] criteria) on the start day of the run-in period; Exclusion Criteria: Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.); Past or current history of severe diabetic complications (proliferative diabetic retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or serious diabetic neuropathy); Fasting blood glucose of >270 mg/dL on the start day of the run-in period or at Week 2 of the run-in period; eGFR of <60 mL/min/1.73 m2 on the start day of the run-in period; Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the start or end day of the run-in period; History of myocardial infarction, unstable angina, or cerebrovascular disorder within 3 months before the start of the run-in period; Concurrent serious (e.g., requiring inpatient hospitalization or surgical intervention) renal or hepatic disease; Past or current history of malignant tumor; however, this criterion shall not apply to those who have been free of relapse for at least 5 years even with a history of malignant tumor. Past or current history of drug hypersensitivity such as shock and anaphylactoid symptoms; Pregnant women, lactating mothers, or women of childbearing potential; Any condition that subjects are assessed to be ineligible by the investigator (sub investigator).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nobuya Inagaki, M.D.
Organizational Affiliation
Kyoto University, Graduate School of Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Kazuoki Kondo, M.D.
Organizational Affiliation
Mitsubishi Tanabe Pharma Corporation
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Tadashi Yoshida, M.D.
Organizational Affiliation
Mitsubishi Tanabe Pharma Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Research site
City
Chugoku
Country
Japan
Facility Name
Research site
City
Kanto
Country
Japan
Facility Name
Research site
City
Kinki
Country
Japan
Facility Name
Research site
City
Kyushu
Country
Japan
Facility Name
Research site
City
Shikoku
Country
Japan
Facility Name
Research site
City
Tohoku
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs